2
and sequenced by Illumina HiSeq™ 2000. Sequence data from genomic DNA and complementary DNA were mapped to the reference human genome (hg19) using the Burrows-Wheeler Aligner and were processed using the publicly available SAMtools, Picard, and Genome Analysis Toolkit. The quantity of gene expression was calculated by the RPKM method( Reads Per Kb per Million reads) [1] . The genes with FDR less 0.001 and change fold more than 2 fold were considered as the DEG (Differentially expressed gene).
Immunohistochemistry
Formalin-fixed, paraffin-embedded ESCC sections were incubated with antibodies to CHI3L1(Abcam, UK), MMP13(R&D systems, USA), SPP1(Abcam, UK) overnight at 4°C. After washing in PBST, the tissue sections were treated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:1000, Zymed). The tissue sections were then developed with 3-diaminobenzidine tetrahydrochloride for 10 seconds, followed by counterstaining with 10% Mayer's hematoxylin. The degree of immunostaining was reviewed by two independent observers.
Results

Cut-off values
As shown in Table S5 Figure S6A and S6B, the AUC of CEA was 0.646 (95% CI: 0.583-0.710) in the test cohort and 0.633 (95% CI: 0.573-0.694) in the validation cohort. Moreover, when we applied 5.0 ng/ml, according to the manufacturer's protocol, for CEA as the cut-off values, as shown in Figure S6B , the sensitivity of CEA was 6.7% and 13.0% in the test and validation cohort, respectively, which is significantly lower than that for the combination (90.00%), which was rather low to apply for the early detection of ESCC. However, the specificity was slightly higher. Moreover, the combination exhibited a higher NPV compared with CEA (87.07% vs. 48.91% in the test cohort, and 93.52% vs.
49.83% in the validation cohort) without an obvious change in the PPV (77.59% vs.
62.5% in the test cohort, and 62.14% vs. 73.33% in the validation cohort).
The association between serum CHI3L1, MMP13 and SPP1 and clinicopathological characteristics
The associations between the median serum CHI3L1, MMP13, SPP1 levels and the clinicopathological parameters are presented in Table S6 . Serum CHI3L1 and MMP13 was not significantly correlated with gender, T classification, N classification, metastasis, or clinical stage, but it was significantly associated with age (P = 0.0002 4 and P = 0.0267, respectively). The serum level of CHI3L1 was higher in elderly patients (≥60 years) than in patients aged less than 60 years, whereas the serum level of MMP13 was lower in elderly patients (≥60 years) than in patients aged less than 60 years. Serum SPP1 was not significantly correlated with age, N classification, metastasis, or clinical stage, but it was correlated with gender and T classification (P = 0.0037 and P =0.0165, respectively). The level of serum SPP1 was elevated in male compared with female patients, and T4 patients exhibited the highest level of SPP1. A.GSE23400 (53N,53T) ; B.GSE20347 (17N,17T) Table S1 . Primers for real-time RT-PCR Table S2 . Pathway analysis of significantly differentially expressed genes. 
ADAM12
Prostate cancer [2] CA9 Breast cancer [3] CHI3L1 Melanoma, [4] breast cancer, [5] ESCC [6] CST11 Colon cancer [7] LAMC2 Pancreatic cancer [8] MMP13 ESCC [9, 10] POSTN Thymoma [11] Table S5. The cut-off values for CHI3L1, MMP13, and SPP1 for each stage.
SERPINE1
Breast cancer [12] SFRP4 Hepatocellular carcinoma [13] SPP1 ESCC [13, 14] Case number of ESCC 
